Targeting the RB tumor suppressor to improve treatment for ER-positive breast cancer
RB tumor suppressor as a therapeutic target in ER-positive breast cancer
This study is looking at how a specific pathway in our cells, called the RB tumor suppressor pathway, influences the treatment of estrogen receptor-positive breast cancer, with the goal of finding better ways to help patients respond to common therapies and overcome challenges when tumors stop responding to treatment.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Roswell Park Cancer Institute Corp NIH-funded |
| Lab location | 1 site (Buffalo, United States) |
| Project ID | NIH-11010047 on NIH RePORTER |
What this research studies
This research investigates the role of the RB tumor suppressor pathway in the treatment of estrogen receptor-positive (ER+) breast cancer. It aims to understand how this pathway affects the response to common therapies, including endocrine treatments and CDK4/6 inhibitors. By analyzing the mechanisms behind therapeutic resistance, the study seeks to develop strategies to enhance treatment effectiveness and overcome challenges posed by tumors that may lose RB function. Patients may benefit from new treatment regimens identified through drug screening and organoid models.
Who could benefit from this research
Good fit: Ideal candidates for this research are women diagnosed with ER-positive breast cancer, particularly those experiencing treatment resistance.
Not a fit: Patients with ER-negative breast cancer or those who do not have a history of treatment resistance may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective therapies for patients with ER-positive breast cancer, potentially improving their treatment outcomes.
How similar studies have performed: Previous research has shown promising results in targeting cell cycle pathways in cancer treatment, indicating that this approach may yield significant advancements.
Where this research is happening
Buffalo, United States
- Roswell Park Cancer Institute Corp — Buffalo, United States (Active)
Researchers
- Principal investigator: Knudsen, Erik — Roswell Park Cancer Institute Corp
- Study coordinator: Knudsen, Erik
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.